Kura Oncology (NASDAQ:KURA) Issues Earnings Results

Key Points

• Kura Oncology beat quarterly expectations: It reported an adjusted loss of $0.77 per share versus the consensus estimate of a $0.88 loss, while revenue of $20.87 million exceeded forecasts of $20.16 million.
• The company remains unprofitable: Kura posted a negative net margin of 411.19% and negative return on equity of 141.95%, despite maintaining strong liquidity with a 6.15 current ratio and minimal debt.
• Analysts remain broadly positive: Ten analysts rate the stock Buy, with an average rating of “Moderate Buy” and an average price target of $25.46, well above its reported trading price near $9.94.

Kura Oncology (NASDAQ:KURA - Get Free Report) issued its quarterly earnings data on Wednesday. The company reported ($0.77) earnings per share for the quarter, topping the consensus estimate of ($0.88) by $0.11, FiscalAI reports. The business had revenue of $20.87 million during the quarter, compared to the consensus estimate of $20.16 million. Kura Oncology had a negative net margin of 411.19% and a negative return on equity of 141.95%.

Kura Oncology Stock Performance

KURA traded up $0.01 on Wednesday, hitting $9.94. 1,132,917 shares of the company traded hands, compared to its average volume of 1,551,446. Kura Oncology has a 12-month low of $6.24 and a 12-month high of $12.49. The company has a 50 day moving average of $10.12 and a 200-day moving average of $9.31. The company has a quick ratio of 6.14, a current ratio of 6.15 and a debt-to-equity ratio of 0.09. The stock has a market capitalization of $882.41 million, a PE ratio of -2.97 and a beta of 0.38.

Insider Activity

In other news, insider Mollie Leoni sold 84,929 shares of the company's stock in a transaction that occurred on Thursday, June 18th. The stock was sold at an average price of $9.82, for a total transaction of $834,002.78. Following the completion of the sale, the insider owned 182,345 shares in the company, valued at $1,790,627.90. This represents a 31.78% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders own 7.60% of the company's stock.

Hedge Funds Weigh In On Kura Oncology

A number of large investors have recently bought and sold shares of KURA. Tower Research Capital LLC TRC boosted its holdings in shares of Kura Oncology by 471.3% in the second quarter. Tower Research Capital LLC TRC now owns 12,071 shares of the company's stock valued at $70,000 after acquiring an additional 9,958 shares in the last quarter. Brevan Howard Capital Management LP acquired a new stake in Kura Oncology in the second quarter valued at about $80,000. Jain Global LLC acquired a new stake in Kura Oncology in the third quarter valued at about $91,000. Lazard Asset Management LLC boosted its holdings in Kura Oncology by 222.3% in the 3rd quarter. Lazard Asset Management LLC now owns 10,423 shares of the company's stock valued at $92,000 after purchasing an additional 7,189 shares in the last quarter. Finally, LPL Financial LLC acquired a new position in Kura Oncology during the 4th quarter worth approximately $105,000.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the stock. Citigroup restated a "market outperform" rating on shares of Kura Oncology in a research note on Thursday, May 28th. Sanford C. Bernstein set a $24.00 target price on Kura Oncology in a research report on Monday, June 15th. Wall Street Zen raised Kura Oncology from a "strong sell" rating to a "hold" rating in a research report on Saturday, May 16th. Wells Fargo & Company set a $24.00 price objective on Kura Oncology in a report on Thursday, June 4th. Finally, Lake Street Capital assumed coverage on shares of Kura Oncology in a report on Tuesday, April 14th. They issued a "buy" rating and a $23.00 target price on the stock. Ten analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Kura Oncology presently has an average rating of "Moderate Buy" and an average price target of $25.46.

Kura Oncology Company Profile

Kura Oncology, Inc NASDAQ: KURA is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura's research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company's lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source